Jean-Luc Lowinski appointed CEO of Pierre Fabre Medicament
The Pierre Fabre Group is pleased to announce the appointment of Jean-Luc Lowinski to the role of CEO of Pierre Fabre Pharmaceuticals, the Group's pharmaceuticals division (PFM).
He assumed his new position on April 1, 2019 and also sits on the Group’s Executive Committee.
Jean-Luc Lowinski, 54, is a veterinarian and holds an MBA from INSEAD. From 1992 to 2012, he pursued his career at Bayer, working primarily abroad—in Japan, South Korea, Singapore, India, Thailand, and China—in the Healthcare and Consumer Care pharmaceutical divisions. In 2012, he joined the Sanofi group, serving at the Shanghai offices as Vice President, Asia—a €2 billion business with a workforce of 10,000 people. Since 2017, he had been Vice President of Emerging Markets at Sanofi Genzyme.
At Pierre Fabre, he is in charge of developing the pharmaceutical activities: oncology, prescription drugs and consumer health care (the Pierre Fabre Health Care, Pierre Fabre Oral Care, and Naturactive franchises). The pharmaceutical division generated €880 million in revenues in 2018, of which 57% was achieved via 29 subsidiaries. The division employs some 6,000 people.